anti-doping is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-05-18. Numbers and descriptions here follow the published literature rather than marketing material.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Human homeostatic iron regulator protein, also known as the HFE protein (High FE2+), is a transmembrane protein that in humans is encoded by the HFE gene. The HFE gene is located on short arm of chromosome 6 at location 6p22.2
=== Michael: All American D-Bag === Michael, who calls himself an all-American badass, picked on William because of his culture and hobbies. It is unknown why this episode has never aired in America. However, it has aired on the Fox8 channel of Foxtel and Austar in Australia. It has never been leaked on the internet, and is not available on the Bully Beatdown website. A preview can be seen at the end of Andy's episode. Michael tapped out five times in the first round and was knocked out with a stomach blow in the second. William won $10,000 and an apology from his bully.
=== Tendonopathy === Tendinopathy refers to a spectrum of tendon disorders, including tendinitis and tendinosis, characterized by pain, swelling, and impaired function of the tendon. Tendon rupture involves the partial or complete tear of the tendon, which can occur acutely or as a result of chronic degeneration. Both conditions are common in athletes and the aging population, but effective treatments and therapies remain limited due to an incomplete understanding of the underlying biology.
International Journal of Pharmaceutics Volume 215 Issue 1-2 Pages 45–50 (2001) Chromatography: Separation and Indirect Detection of Amino-acids by Reversed Phase ion-pair Chromatography. Journal of Chromatographic Science Volume 31 Issue 11 Pages 480-485 (1993) Determination of pore/protein size via electrophoresis and slit sieve model. Electrophoresis Volume 25 Issue 17 Pages 2907-2911 (2004)
Burkett (1984), award-winning correspondent for WABC-TV Matthew Cooper (1984), Time magazine White House correspondent and defendant in the Valerie Plame investigation Tom Watson (1984), journalist, entrepreneur Thomas Vinciguerra (1985), journalist, editor and author Naftali Bendavid (1986), Congress correspondent for The Wall Street Journal Susan Benesch (1986), journalist, free speech advocate Elizabeth Rubin (1987), journalist for The New York Times Magazine, sister of Bloomberg News executive editor James Rubin '82 Aram Roston (1988), investigative journalist Edward Lewine (1989), author and freelance journalist Sam Marchiano (1989), television sportscaster, documentarian and activist, daughter of sportscaster Sal Marchiano David Streitfeld (1989), book reporter for The Washington Post; winner of the 2013 Pulitzer Prize for Explanatory Reporting Caroline Glick (1991), Israeli journalist, editor, writer Warren St. John (1991), journalist for The New York Times and former CEO of Patch Michael J. Socolow (1991), broadcast journalist and professor at the University of Maine Jesse Eisinger (1992), Pulitzer Prize-winning reporter for ProPublica Jean H.
Sources: en.wikipedia.org
=== Kentucky === In 2005, a bill was introduced that would require 80 hours of didactic and practical training, plus 50 hours of clinical training, and certification as a phlebotomy technician for phlebotomy, that did not pass.
== Safety == TCFH does not irritate skin but is a potent eye irritant. The sensitization potential of TCFH was shown to be low compared to other amide bond forming agents, which can be used in the context of peptide synthesis (it is non-sensitizing at 1% in the local lymph node assay according to OECD 429). The major by-product of using TCFH is tetramethylurea, which has demonstrated teratogenic activity in several laboratory animal species.
=== Attention deficit hyperactivity disorder === Atomoxetine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD). It is approved for use in children, adolescents, and adults. However, its efficacy has not been studied in children under six years old. One of the primary differences with the standard stimulant treatments for ADHD is that it has no known misuse potential. Meta-analyses and systematic reviews have found that atomoxetine has comparable efficacy and equal tolerability to methylphenidate in children and adolescents. In adults, efficacy and tolerability are equivalent. The benefits of atomoxetine against ADHD symptoms are dose-dependent until a plateau is reached. While its efficacy may be less than that of lisdexamfetamine, there is some evidence supporting its use in combination with stimulants. Doctors may prescribe non-stimulants including atomoxetine when a person has bothersome side effects from stimulants; when a stimulant was not effective; in combination with a stimulant to increase effectiveness; when the cost of stimulants is prohibitive; or when there is concern about the misuse potential of stimulants in a patient with a history of substance use disorder. Atomoxetine, similarly to stimulants, appears to reduce emotional lability associated with ADHD in adults. Atomoxetine is thought to alleviate ADHD symptoms through norepinephrine reuptake inhibition and by indirectly increasing dopamine levels in the prefrontal cortex, sharing 70–80% of the brain regions with stimulants in its produced effects.
== January 21, 1982 (Thursday) == By a margin of 55% to 45%, the 498,000 members of the Britain's national coal workers union voted to accept a 9.3% pay offer, despite the recommendation of union president-elect Arthur Scargill to reject the proposal. Died: Ned Irish, 76, American NBA team owner and founder of the New York Knicks, and enshrinee in the Basketball Hall of Fame. William Luneberg, 69, president of the American Motors Corporation (AMC) who developed the company as the fourth largest automaker in the U.S. (after General Motors, Ford Motor Company, and Chrysler Corporation)
Serology for hepatitis viruses, autoantibodies (ANA, anti-smooth muscle, antimitochondria, anti-LKM) Ferritin and transferrin saturation: markers of iron overload as in hemochromatosis, copper and ceruloplasmin: markers of copper overload as in Wilson's disease Immunoglobulin levels (IgG, IgM, IgA) – these immunoglobulins are nonspecific, but may help in distinguishing various causes. IgG level is elevated in chronic hepatitis, alcoholic hepatitis, and autoimmune hepatitis. It is a slow and sustained increase is seen in viral hepatitis. IgM significantly increased in primary biliary cirrhosis and moderately increased in viral hepatitis and cirrhosis. IgA is increased in alcoholic cirrhosis and primary biliary cirrhosis. Cholesterol and glucose Alpha 1-antitrypsin Markers of inflammation and immune cell activation are typically elevated in cirrhotic patients, especially in the decompensated disease stage:
Sources: en.wikipedia.org
Since thaumatin crystallizes very quickly and easily in the presence of tartrate ions, thaumatin-tartrate mixtures are frequently used as model systems to study protein crystallization. The solubility of thaumatin, its crystal habit, and mechanism of crystal formation are dependent upon the chirality of precipitant used. When crystallized with L- tartrate, thaumatin forms bipyramidal crystals and displays a solubility that increases with temperature; with D- and meso-tartrate, it forms stubby and prismatic crystals and displays a solubility that decreases with temperature. This suggests control of precipitant chirality may be an important factor in protein crystallization in general.
=== Granulation === In general, there are two types of granulation: wet granulation and dry granulation. Granulation can be thought of as the opposite of milling; it is the process by which small particles are bound together to form larger particles, called granules. Granulation is used for several reasons. Granulation prevents the "demixing" of components in the mixture, by creating a granule which contains all of the components in their required proportions, improves flow characteristics of powders (because small particles do not flow well), and improves compaction properties for tablet formation.
As the nascent polypeptide elongates during proteosynthesis, it passes through the ribosomal tunnel, interacting with the tunnel walls, thus regulating the rate at which it passes through the tunnel. This in turn affect the rate of partial folding, which may already occur at this stage. Short stretches of alpha-helix may form in the inner part of the tunnel and tertiary structure may start forming in the wider tunnel vestibule. As the N-terminus reaches the tunnel exit and is processed by the ribosome-associated protein biogenesis factors, the tertiary structure formed in the tunnel may partially refold. The folding is then completed when the C-terminus is released from the PTC and the protein escapes the tunnel.
==== Motivational Enhancement Therapy ==== Motivational enhancement therapy (MET) is the manualized form of motivational interviewing (MI). MI leverages one's intrinsic motivation to recover through education, formulation of relapse prevention strategies, reward for adherence to treatment guidelines, and positive thinking to keep motivation high—which are based on a person's socioeconomic status, gender, race, ethnicity, sexual orientation, and readiness to recover. Like CBT, MET alone has not shown convincing efficacy for OUD. There is stronger support for combining it with other therapies.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.